Stay connected

Sign up today to receive helpful information and resources about CABLIVI and aTTP.

*Required field.

*

You must be at least eighteen (18) years or older to enroll. We will not sell or transfer your Personal Data to any unrelated third party for marketing purposes without your express permission. We may also share such Personal Data with regulatory authorities, if required, or contact you to conduct market research. By selecting “SUBMIT”, you authorize Genzyme Corporation and its affiliates, including but not limited to, Sanofi S.A. (together, “Sanofi Genzyme”), and companies working with Sanofi Genzyme, to contact you by mail, email, and/or telephone, including calls and text messages made using an automatic telephone dialing system or a prerecorded voice at the telephone number(s) provided to provide you with the information you requested and other related information and services or programs that Sanofi Genzyme offers or sponsors, or other topics of interest. You understand that you are not required to provide this consent as a condition of purchasing any property, goods, or services from Sanofi Genzyme. To learn more about how your personal information is used or if you decide that you no longer want to receive information about Sanofi Genzyme products and services, please visit www.sanofigenzyme.com/en/privacy-policy.

IMPORTANT SAFETY INFORMATION

Who should not take CABLIVI?

Do not take CABLIVI if you’ve had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.

What should I tell my healthcare team before starting CABLIVI?

Tell your doctor if you have a medical condition including if you have a bleeding disorder. Tell your doctor about any medicines you take.

Talk to your doctor before scheduling any surgery, medical or dental procedure.

What are the possible side effects of CABLIVI?

CABLIVI can cause severe bleeding. In clinical studies, severe bleeding adverse reactions of nosebleed, bleeding from the gums, bleeding in the stomach or intestines, and bleeding from the uterus were each reported in 1% of subjects. Contact your doctor immediately if excessive bleeding or bruising occur.

You may have a higher risk of bleeding if you have a bleeding disorder (i.e. hemophilia) or if you take other medicines that increase your risk of bleeding such as anti-coagulants.

CABLIVI should be stopped for 7 days before surgery or any medical or dental procedure. Talk to your doctor before you stop taking CABLIVI.

The most common side effects include nosebleed, headache and bleeding gums.

Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of CABLIVI. Call your doctor for medical advice about side effects.

INDICATION

What is CABLIVI?

CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.

Back to the top